| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Zawitz David | Chief Operating Officer | C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER | /s/ Jayson Rieger, Attorney-in-Fact | 2025-11-25 | 0002046750 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRCA | Common Stock | Purchase | $42.4K | +10K | +90.91% | $4.24 | 21K | Nov 25, 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRCA | Series C Warrant (right to buy) | Purchase | +2.5K | 2.5K | Nov 25, 2025 | Common Stock | 2.5K | $6.32 | Direct | F2, F3 |
| Id | Content |
|---|---|
| F1 | Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split. |
| F2 | Immediately exercisable. |
| F3 | The reported securities are included within 10,000 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. |